VTRS: Viatris Inc. Stock

by  •  • Comments Off on VTRS: Viatris Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 13,201.14
Enterprise Value ($M) 27,072.54
Book Value ($M) 19,792.40
Book Value / Share 16.58
Price / Book 0.67
NCAV ($M) -13,654.00
NCAV / Share -11.44
Price / NCAV -0.97

Profitability (mra)
Return on Invested Capital (ROIC) -0.02
Return on Assets (ROA) -0.02
Return on Equity (ROE) -0.04

Liquidity (mrq)
Quick Ratio 0.96
Current Ratio 1.51

Balance Sheet (mrq) ($M)
Current Assets 11,307.70
Assets 44,754.10
Liabilities 24,961.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-24 13G Davis Selected Advisers
2024-02-13 13G/A Vanguard Group Inc 11.86 -4.73
2024-01-30 13G/A State Street Corp 5.17 0.11
2024-01-26 13G/A BlackRock, Inc. 7.70 -0.94

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   For the Fiscal Year Ended December 31, 2023 OR ☐ Transition
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 1,793,880 7,667,391 23.40
2025-02-20 1,773,565 5,834,941 30.40
2025-02-19 1,408,501 5,553,728 25.36
2025-02-18 1,785,096 6,226,966 28.67

(click for more detail)

Similar Companies
VIR – Vir Biotechnology, Inc. VOR – Vor Biopharma Inc.
VRTX – Vertex Pharmaceuticals Incorporated VTYX – Ventyx Biosciences, Inc.
VYGR – Voyager Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io